CN1310659C - Tongue dropping medicine pill for diminishing inflammation and detoxicating - Google Patents
Tongue dropping medicine pill for diminishing inflammation and detoxicating Download PDFInfo
- Publication number
- CN1310659C CN1310659C CNB2005100128078A CN200510012807A CN1310659C CN 1310659 C CN1310659 C CN 1310659C CN B2005100128078 A CNB2005100128078 A CN B2005100128078A CN 200510012807 A CN200510012807 A CN 200510012807A CN 1310659 C CN1310659 C CN 1310659C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- present
- grams
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 20
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 19
- 239000006187 pill Substances 0.000 title claims description 14
- 230000003467 diminishing effect Effects 0.000 title 1
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 11
- 239000003053 toxin Substances 0.000 claims abstract description 11
- 231100000765 toxin Toxicity 0.000 claims abstract description 11
- 229910021538 borax Inorganic materials 0.000 claims abstract description 9
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 9
- 239000004863 Frankincense Substances 0.000 claims abstract description 8
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 14
- 241000717739 Boswellia sacra Species 0.000 claims description 9
- 244000293323 Cosmos caudatus Species 0.000 claims description 9
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 9
- 241001057584 Myrrha Species 0.000 claims description 9
- 239000009286 sanguis draxonis Substances 0.000 claims description 9
- 241000283956 Manis Species 0.000 claims description 8
- 241000131808 Scolopendra Species 0.000 claims description 7
- 241000245240 Lonicera Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 39
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 229910052957 realgar Inorganic materials 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000271309 Aquilaria crassna Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 239000003088 amphibian venom Substances 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 208000030270 breast disease Diseases 0.000 abstract 1
- 229910052956 cinnabar Inorganic materials 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000011049 pearl Substances 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000000843 powder Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 11
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- 235000011158 Prunus mume Nutrition 0.000 description 4
- 244000018795 Prunus mume Species 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 206010007882 Cellulitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical group [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine material, more specifically a medicine Dianshe Wan for antiphlogosis and detoxification. The present invention solves the problems of single efficiency and poor therapeutic effect in the comprehensive treatment of various kinds of inflammation, such as sores and ulcers, breast diseases, tumours, gall and skin diseases existing in the prior art. The present invention is formed by the preparation of saffron, safflower, realgar, toad venom, frankincense, myrrh, dragon's blood, eaglewood wood, borax, dandelions, rhubarb, semen lepidii, pangolins, bezoar, musk, pearls, bear gall, centipedes, honeysuckle flowers, cinnabar and borneol. The medicine of the present invention has the functions of heat clearing, antiphlogosis, blood cooling, expulsion of toxin, detumescence, acesodyne, pathogenic infection resistance, tumor inhibition and immunity enhancement. The present invention has the advantages of low toxicity and large safety factor, and the total effective rate can reach more than 90 percent through clinical use.
Description
Technical field
The present invention relates to a kind of Chinese medicine, specifically is a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin.
Background technology
Skin infection, the general designation of all surgical diseasess, rise and mainly show as all kinds of organ irritation at the skin infection place, all skin ulcers of dispute, laryngopharynx swelling and pain, the tooth boundary swells and ache; Skin superficial face acute festering type infects; Furuncle, face, extremity merge acute lymphangitis; External carbuncle, shallow surperficial abscess, acute lymphoblastic inflammation; Carbuncle on the back, the acute cellulitis of shallow soft tissue; Erysipelas, the actute infection that the skin burst is red.All kinds of cystic hyperplasia of breast, acute mastitis, acute suppuration type mastitis; Nodules of the breast, mammary gland fibroma, cystic hyperplasia of breast, cyclomastopathy; Breast carcinoma, breast carcinoma; All kinds of tumors are as nodular varicosity, angioma, osteoma, sarcoma, hysteromyoma, ovarian cyst etc.Some dermatosiss belong to pyretic toxicity and qi stagnation blood stasis disease as various skin sore (acne, frustrate skin ulcer, comedo) herpes, mottle, infantile malnutrition etc.Above-mentioned disease pilosity is common, and mostly effect is single for existing medicine on the market, and is with strong points, is difficult to realize comprehensive therapy.
Summary of the invention
The present invention is in order to solve all kinds of inflammation of the Comprehensive Treatment that exists in the prior art, skin infection, and cystic hyperplasia of breast, tumor, effect is single in wart and the dermatosis, and is with strong points, the inapparent problem of curative effect and a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin is provided.
The present invention is realized by following technical scheme, a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin, and it is formulated by weight by following Chinese herb medicine:
190～210 parts of 126～146 portions of Realgars of 10～14 parts of Flos Carthamis of Stigma Croci
110～130 parts of 110～130 parts of Myrrhas of 60～70 parts of Olibanums of Venenum Bufonis
70～90 parts of 70～90 parts of Boraxs of 35～45 portions of Lignum Aquilariae Resinatum of Sanguis Draxonis
35～45 parts of 110～130 parts of Semen Lepidii (Semen Descurainiae)s of 230～250 parts of Radix Et Rhizoma Rhei of Herba Taraxaci
3～5 parts in 3～5 parts of Moschus of 150～170 parts of Calculus Boviss of Squama Manis
6.5～8.5 parts of 1～3 part of Scolopendras of 1～3 part of Fel Ursi of Margarita
35～45 parts of 310～330 parts of Borneolum Syntheticums of 150～170 parts of Cinnabaris of Flos Lonicerae
Stigma Croci (having another name called Stigma Croci), acrid in the mouth, sweet, bitter, warm in nature.It is the activating blood circulation to dissipate blood stasis medicine of using always.This product can go into that heart channel is double goes into the expense warp, for the blood stasis stagnation of QI or the obstructed innominate toxic swelling that causes of QI and blood better curative effect is arranged, and gynecological uses Stigma Croci many especially, be used in the blood stasis amenorrhea, or menstrual blood volume is few, and the clot of having passed through is through symptoms such as after date prolong.
Margarita is a rare Chinese medicine, and cold in nature, sweet in the mouth becomes; Function has that arresting convulsion is calmed the nerves, the heat clearing away tonifying YIN, and cure mainly cardiopalmus and be insomnia, the external treatment conjunctival congestion, heart-fire falls in diseases such as carbuncle, removing heat from the liver, the liver-yang of diving, tranquilizing mind.
Sanguis Draxonis, flat, the sweet-salty of property, function is the blood stasis expelling hemostasis, expelling pus and promoting granulation, traumatic injury, the breast abdomen pain of becoming silted up that cures mainly for oral administration, external skin ulcer are hindered and disease such as are not held back.
Venenum Bufonis, warm in nature, sweet in the mouth is hot, the function removing toxic substances and promoting subsidence of swelling cures mainly diseases such as carbuncle poison furuncle, laryngopharynx swelling and pain.
Moschus, acrid in the mouth, warm in nature, function is happy key, the meridian dredging, about current 12 warps, interior deep marrow, outer thorough fur, the sharp key of kind switch has dredge the meridian passage, promoting the circulation of QI to relieve pain, subduing inflammation, the effect that removes tumor.
Venenum Bufonis, Olibanum, Myrrha, Squama Manis need just can be used as medicine after the reduction toxicity through concocting, and concocting method is existing pharmaceutical industry conventional method.
Medicine of the present invention is based on treatment by oral administration of medicines, and external treatment is auxilliary.Treatment by oral administration of medicines sets out with organic conception, at three processes of surgical diseases, that is: from the beginning of, become pus, after bursting, found out the Comprehensive Treatment principle that disappears, holds in the palm, mends, heat-clearing and toxic substances removing, detumescence, pain relieving.Compatibility of drugs of the present invention, suit the medicine to the illness more to because of.Select Calculus Bovis, Venenum Bufonis removing toxic substances and promoting subsidence of swelling for use; Moschus, Borneolum Syntheticum the meridian dredging, subduing inflammation; Realgar is separated and poisons silt; Margarita, Cinnabaris detoxifcation mind calming; Promoting blood circulation and stopping pain such as Sanguis Draxonis, Olibanum, Myrrha; Semen Lepidii (Semen Descurainiae) is the key of eliminating the pathogens from the lung Dingchuan, with the same usefulness of Lignum Aquilariae Resinatum, broken hard merit by heresy is arranged; Borax is the medicine of detoxifcation, removing heat-phlegm, and the main component of Borax is a sodium tetraborate, to the mucocutaneous effect that the convergence protective effect is arranged and suppress some bacterial growth; The Radix Et Rhizoma Rhei anti-inflammation, antitumor enhancing immunity function.All in a word medicines share and gather the effect that reaches detoxifcation, detumescence, pain relieving altogether.
Medicine preferred agents of the present invention is composed as follows:
64 parts of 200 parts of Venenum Bufoniss of 136 portions of Realgars of 12 parts of Flos Carthamis of Stigma Croci
80 parts of 40 portions of Lignum Aquilariae Resinatum of 120 parts of Sanguis Draxonis of 120 parts of Myrrhas of Olibanum
40 parts of 120 parts of Semen Lepidii (Semen Descurainiae)s of 240 parts of Radix Et Rhizoma Rhei of 80 parts of Herba Taraxacis of Borax
2 parts of 4 parts of Margaritas of 4 parts of Moschus of 160 parts of Calculus Boviss of Squama Manis
320 parts in 160 parts of Cinnabaris of 7.5 portions of Flos Loniceraes of 2 parts of Scolopendras of Fel Ursi
40 parts of Borneolum Syntheticums
The preparation technology of the medicine of heat-clearing and toxic substances removing of the present invention is: accurately take by weighing the medical material of above-mentioned various components by weight, in the every kind of clean container of packing into; Pulverize respectively according to the pulverizing medicinal materials standard operating procedure, Cinnabaris, Realgar, crushing pearl are the impalpable powder standard, to remove Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis all the other 13 flavor pulverizing medicinal materials in addition again and become fine powder, with above-mentioned all fine powders mix back (suitably reserve part Cinnabaris fine powder keep supplying clothing with) again with Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis facing-up, sieve mix homogeneously, standard; Sterilization is also checked microbiological indicator; Make the watered pill at last.
Medicine of the present invention has: the function of heat clearing and inflammation relieving, removing heat from blood toxin expelling, reducing swelling and alleviating pain, inhibition tumor, enhancing immunity.
Be mainly used in treatment nameless gall, various malignant boil from the beginning of, carbuncle, furuncle carbuncle on the back, aphtha of the mouth and tongue erosion, various inflammation such as gingival swelling and pain, headache conjunctival congestion, laryngopharynx swelling and pain, hematemesis and epistaxis, youth carbuncle on the back; Esophageal carcinoma, gastric cancer breast carcinoma and hepatocarcinoma all there is significant curative effect.
Through the modern medicine experimental verification, beneficial effect of the present invention is:
One, disease-resistant source microorganism, to gram positive bacteria, tubercule bacillus, bacillus pyocyaneus, golden staphylococci, micrococcus catarrhalis etc. have stronger inhibitory action to described medicine in the present invention.Alpha streptococcus, pneumonia and dermatophytes also there is inhibitory action.Clinical being mainly reflected on all kinds of inflammation of treatment has better curative effect.
Two, enhancing immunity and antitumor efficacy (being zoopery down):
1, animal: select for use animal to watch brood chamber 18-24 gram Kunming kind healthy mice 615 and 675 mouse inbred liness, male and female dual-purpose.
2, tumor strain: be this chamber long-term 5-180 of going down to posterity, 615 and lerus pulmonary carcinoma that transplants on animal body.
3, medicine: medicine of the present invention, Co., Ltd provides by the double Pharmaceutical in Shanxi.
Cyclophosphamide, 200MG/ props up, the injectable powder that Shanghai No.12 Pharmaceutical Factory produces, lot number 830107.
Hydrocortisone, 25MG|/5ML Tianjin people pharmaceutical factory produces, lot number 820815.
4, method
(1) immune organ weight is measured; Measure medicine of the present invention respectively to normal mouse, tumor-bearing mice be subjected to cyclophosphamide to suppress the back Turnover of Mouse Peritoneal Macrophages to engulf vigor.
(2) macrophage phagocytic function is measured; Measure medicine normal mouse of the present invention, tumor-bearing mice respectively and be subjected to hydrocortisone to suppress the back Turnover of Mouse Peritoneal Macrophages and engulf vigor.
(3) HC50 measures; Substantially measure according to the haemolysis Qin algoscopy of Xu Xueying report and carry out.
Experimental result
1, to mouse immune organ weight's influence.
1.1 influence to the immune organ weight of normal mouse;
The kunming mice of 18-22 gram is selected in experiment for use, random packet, and continuous oral dispensing seven days, and next day is put to death animal in drug withdrawal, cuts open and gets thymus and index and spleen index: (the results are shown in Table 1)
Heavy and heavy (the mg)/body weight (g) of spleen of thymus and index and spleen index=thymus
Table 1
| Group | Matched group | Medicine one of the present invention | Medicine two of the present invention | |
| Dosage regimen g/kg/ day * days | —— | 1.0×7 | 0.5×7 | |
| Number of animals | 10 | 10 | 10 | |
| Body weight (gram) | Beginning | 21.0 | 19.5 | 20.0 |
| The end | 26.6 | 26.8 | 27.9 | |
| Thymus index * ± SE | 4.06±0.21 | 6.01±0.35 | 6.80±0.31 | |
| The P value | —— | ＜0.01 | ＜0.01 | |
| Index and spleen index * ± SE | 5.06±0.34 | 6.89±0.32 | 9.31±0.45 | |
| The P value | —— | ＜0.01 | ＜0.01 | |
By 1 table as seen, medicine of the present invention can obviously increase the weight of normal mouse thymus and spleen.It is particularly outstanding to increase animal spleen weight with 0.5/g/kg/ day * days dosage, and there were significant differences with matched group.
1.2 to using cyclophosphamide mouse immune organ weight's influence:
Experiment is basic with 1.1 administrations.Pressed 75mg/kg dosage in first day, intraperitoneal injection of cyclophosphamide is 3 days continuously.(result is as shown in table 2)
Table 2
| Group | Matched group | Medicine one of the present invention | Medicine two of the present invention | Normal control | |
| Dosage regimen g/kg/ day * sky | —— | 1.0×7 | 0.5×7 | Do not inoculate S)-180 | |
| Number of animals | 9 | 10 | 19 | 10 | |
| Body weight (gram) | Beginning | 21.0 | 20.5 | 27.8 | 21.0 |
| The end | 24.6 | 26.0 | 27.9 | 26.6 | |
| Thymus index * ± SE | 1.68±0.14 | 2.64±0.32 | 3.76±0.38 | 4.06±0.21 | |
| The P value | —— | ＜0.001 | ＜0.001 | 0.001 | |
| Index and spleen index * ± SE | 2.78±0.17 | 4.17±0.33 | 4.96±0.50 | 5.06±0.34 | |
| The P value | —— | ＜0.001 | ＜0.001 | 0.001 | |
Table 2 is finding as a result, and medicine 0.5g/kg of the present invention just can obviously resist the immunization of cyclophosphamide.Animal immune the organ weight significantly go up, near the weight of normal mouse spleen.
1.3 influence to tumor-bearing mice:
Conventional inoculation S-180, next day, random packet and continuous oral administration were seven days, put to death animal after the drug withdrawal, cutd open to get thymus and spleen is weighed.(the results are shown in Table 3)
The influence of table 3 pair tumor-bearing mice immune organ weight
| Group | Matched group | Medicine one of the present invention | Medicine two of the present invention | Normal control | |
| Dosage regimen g/kg/ day * sky | —— | 1.0×7 | 0.5×7 | Do not inoculate S)-180 | |
| Number of animals | 10 | 10 | 10 | 10 | |
| Body weight (gram) | Beginning | 21.0 | 20.5 | 21.5 | 21.0 |
| The end | 25.0 | 26.0 | 28.0 | 26.6 | |
| Thymus index * ± SE | 3.84±0.39 | 5.47±0.27 | 6.15±0.31 | 4.06±0.21 | |
| The P value | —— | ＜0.01 | ＜0.01 | ＞0.05 | |
| Index and spleen index * ± SE | 6.60±0.50 | 10.02±0.59 | 13.90±0.71 | 5.06±0.34 | |
| The P value | —— | ＜0.001 | ＜0.001 | 0.001 | |
Experiment shows that medicine of the present invention can significantly strengthen the weight of the immune organ of tumor animal.Its 0.5g/kg dosage increase animal spleen heavily is two times of matched group.
2. to the huge influence of biting function of mouse peritoneal
2.1 influence to normal macrophage phagocytosis of mice:
Select 18～22 gram Kunming mouses for use, random packet and continuous oral administration seven days, put to death the back.Every animal is dripped about 0.2ml flushing liquor on microscope slide all with the Hanks liquid flushing abdominal cavity of 2.5ml, and 37 ℃ of temperature were incubated 30 minutes, washed away the cell that drips the not obedient wall that suspends on the sheet with normal saline.Methanol is fixed, Ji Mu Sa-Wright's stain dyeing.Observation is huge under the oil mirror bites Sanguis Gallus domesticus ball situation and is calculated as follows phagocytic percentage.(the results are shown in Table 4)
Phagocytic percentage=(engulfing the phagocyte number/observation macrophage sum of Sanguis Gallus domesticus ball) 100%
Table 4
| Group | Dosage regimen g/kg/ days | Number of animals | Engulf percent * ± SE | The P value |
| Matched group | —— | 10 | 50.0±3.64 | —— |
| Medicine 1 of the present invention | 1.0×7 | 9 | 72.4±2.53 | ＜0.01 |
| Medicine 2 of the present invention | 0.5×7 | 10 | 87.60±3.48 | ＜0.01 |
The result shows that medicine normal mouse phagocytosis of macrophages of the present invention has obvious potentiation.0.5g/kg its phagocytic rate of dosage be 87% with matched group relatively there were significant differences (P＜0.01).
2.2 influence to the macrophage phagocytosis of mice that is subjected to hydrocortisone
The experiment basic step is the same, only presses 5g/kg dosage lumbar injection hydrocortisone 2 days in the time of administration.(the results are shown in Table 5).
Table 5
| Group | Dosage regimen g/kg/ days | Number of animals | Engulf percent * ± SE | The P value |
| Matched group | —— | 10 | 50.0±3.64 | —— |
| Medicine one of the present invention | 1.0×7 | 9 | 72.4±2.53 | ＜0.01 |
| Medicine two of the present invention | 0.5×7 | 10 | 87.60±3.48 | ＜0.01 |
| Normal control | Not injecting hydrogen examines | 10 | 50.50±3.64 | ＜0.05 |
The result shows that each dosage group of medicine of the present invention all can significantly improve the Turnover of Mouse Peritoneal Macrophages phagocytic function that hydrocortisone suppresses.Its phagocytic percentage has returned to normal level.
2.3 to the huge influence of biting function of the macrophage of tumor-bearing mice
18～22 gram C57 mouse inbred liness are selected in experiment for use, conventional inoculation Lerus pulmonary carcinoma.Next day, random packet and continuous oral administration were 7 days, a same experiment of following steps.(the results are shown in Table 6)
Table 6
| Group | Dosage regimen g/kg/ days | Number of animals | Engulf percent * ± SE | The P value |
| Matched group | —— | 10 | 18.50±4.84 | —— |
| Medicine one of the present invention | 1.0×7 | 9 | 76.40±1.73 | ＜0.001 |
| Medicine two of the present invention | 0.5×7 | 10 | 87.70±4.05 | ＜0.001 |
| Normal control | Do not inoculate the tumor strain | 10 | 50.50±3.64 | ＜0.01 |
As seen bite function when extremely low when the tumor-bearing mice peritoneal macrophage is huge, medicine of the present invention just can significantly improve its phagocytic rate, and increase rate reaches nearly five times.
3. the influence that mice serum hemolysin (HC50) is formed
18～22 grams, 615 mouse inbred liness, male and female half and half are selected in experiment for use.Method adopts the sanguinin algoscopy of Xu Xue beautiful jade report substantially.With mice random packet continuous oral seven days.Every Mus is accepted sheep red blood cell (SRBC) 0.2ml simultaneously after the drug withdrawal.Immunity once, after four days the eye frame get blood, separation of serum.Serum is got 1ml after diluting by 1: 50 with N5, adds 0.5mlCRBC and 1ml complement, and temperature was incubated 10 minutes, and is centrifugal behind the ice bath.Get supernatant 1ml, add 3ML Dou Shi reagent, measure the hemoglobin content that discharges in the sheep blood cell haemolysis process with spectrophotometer at wavelength 540nm place then.Ask half hemolysis value HC50 by following formula.Reflect the immune situation of animal body fluid with this.(the results are shown in Table 7)
Table 7
| Group | Dosage regimen g/kg/ days | Number of animals | HC50 ×±SE | The P value |
| Matched group | —— | 10 | 9.60±1.84 | —— |
| Medicine one of the present invention | 1.0×7 | 10 | 19.19±0.77 | ＜0.001 |
| Medicine two of the present invention | 0.5×7 | 9 | 23.50±0.85 | ＜0.001 |
Experiment shows that medicine of the present invention can significantly promote the antibody of mice to generate, and its HC50 is apparently higher than matched group.
Three, antitumor action experiment
(1), to the inhibitory action of mice transplanted tumor
Experiment material and method
1, medicine and preparation: laboratory sample is a medicine of the present invention.
2, animal: body weight 18～22 gram kunming mices, male and female half and half.
3, tumor strain: be that this chamber is transplanted mouse entity type cervical cancer U-14, sarcoma S-180, sarcoma S-37 and ascites tumor S-180A and the ehrlich ascites tumor ECA that goes down to posterity on one's body for a long time animal.
Experimental technique: according to conventional method inoculation kind of tumor.Inoculation separates animal next day at random, and the beginning administration.Administration oral drug suspension 0.5ml/20g every day body weight, matched group is given the equal-volume solvent, continuous 7-14 days once a day.The result by following table 8 as seen.
Table 8
| The tumor strain | Experiment number | Dosage g/kg/ day * sky | Number of animals | Body weight (g) | Tumor heavy (g) or existence natural law | The P clay | ||||
| Beginning | The end | Beginning | The end | White increment | Meansigma methods ± standard value | Suppression ratio or increase in life span | ||||
| S-180 | 1 | - 1×10 | 14 10 | 12 10 | 21.00 20.00 | 24.75 22.95 | 0.38 0.30 | 3.17±0 1.92±0.42 | - 39.43 | ＜0.01 |
| 2 | - 1×10 | 10 10 | 9 9 | 19.00 20.00 | 27.33 26.61 | 0.83 0.66 | 3.47±0 2.06±0.42 | - 40.63 | ＜0.01 | |
| 3 | - 1×10 | 10 10 | 8 9 | 23.00 22.00 | 27.81 25.56 | 0.48 0.36 | 2.44±0 1.10±039 | - 54.92 | ＜0.01 | |
| u-14 | 1 | - 1×14 | 10 10 | 9 10 | 20.00 21.00 | 25.72 26.20 | 0.57 0.52 | 2.94±0 1.75±0.41 | - 40.48 | ≤0.01 |
| 2 | 1- 1×14 | 10 10 | 8 10 | 23.00 22.00 | 24.88 23.20 | 0.19 0.12 | 3.30±0 1.92±0.56 | - 41.82 | ＜0.05 | |
| S-37 | - 1×7 | 10 10 | 8 8 | 23.00 22.00 | 25.81 25.00 | 0.28 0.30 | 4.03±0 2.54±0.66 | - 36.97 | ＜0.05 | |
| EAC | 1 | - 1×1 | 10 10 | 10 9 | 19.50 19.00 | 24.80 24.35 | 0.53 0.54 | 12.10±0 18.10±2.16 | - 39.67 | ＜0.05 |
| 2 | - 1×7 | 10 10 | 10 10 | 20.00 19.00 | 25.03 24.34 | 0.50 0.53 | 11.70±0 14.10±1.18 | - 20.51 | ≥0.05 | |
| 3 | - 1×7 | 10 10 | 10 10 | 19.50 19.00 | 25.60 24.31 | 0.61 0.53 | 12.70±0 16.70±1.27 | - 31.50 | ＜0.01 | |
| S-180A | 1 | - 1×7 | 10 10 | 10 10 | 20.00 22.00 | 24.80 25.53 | 0.48 0.53 | 12.70±0 16.70±1.61 | _ 31.50 | ＜0.05 |
| 2 | - 1×7 | 10 10 | 10 10 | 19.00 25.10 | 24.03 25.10 | 0.50 0.61 | 11.10±0 13.80±1.89 | - 24.32 | ＞0.05 | |
Medicine of the present invention all has in various degree inhibitory action to mice transplanted tumor, but more more remarkable than film edema type to the inhibitory action of solid type tumor.
(2), preventive administration is to the influence of mouse entity type tumor, it the results are shown in following table 9
Learn by statistics and handle, find that administration in advance has certain inhibitory action to tumor growth, and the inhibitory action of successive administration is obvious after inoculating.
Table 9
| The tumor strain | Dosage mg/kg/ day * sky | Number of animals | Body weight (g) | Tumor weight (g) | The P value | ||||
| Beginning | The end | The increment of day at the whole story | Average tumor weight ± standard error | Suppression ratio | |||||
| S-180 | 0×7 | 10 | 10 | 19.5 | 28.45 | 1.28 | 2.53±0 | ||
| 250×7 | 10 | 8 | 20.50 | 27.78 | 1.04 | 1.99±0.36 | 21.34 | ＞0.05 | |
| 500×7 | 10 | 9 | 20.50 | 27.03 | 0.93 | 1.60±0.28 | 36.76 | ＜0.01 | |
| 0×14 | 10 | 10 | 20.00 | 29.75 | 0.70 | 3.32±0 | |||
| 250×14 | 10 | 10 | 19.00 | 32.75 | 0.98 | 2.07±0.37 | 37.65 | ＜0.01 | |
| 500×14 | 10 | 10 | 20.50 | 28.68 | 0.58 | 1.48±0.30 | 55.42 | ＜0.001 | |
| 0×21 | 10 | 10 | 20.00 | 29.51 | 0.45 | 3.12±0 | |||
| 250×21 | 10 | 10 | 19.00 | 29.38 | 0.49 | 1.71±0.36 | 45.19 | ≤0.001 | |
| 500×21 | 10 | 9 | 19.50 | 30.42 | 0.52 | 1.28±0.36 | 58.97 | ＜0.001 | |
| U-14 | 0×7 | 10 | 10 | 19.50 | 28.78 | 1.33 | 3.79±0 | ||
| 250×7 | 10 | 10 | 19.50 | 27.50 | 1.14 | 2.02±0.55 | 46.70 | ＜0.01 | |
| 500×7 | 10 | 10 | 21.50 | 27.65 | 0.88 | 1.59±0.59 | 58.05 | ＜0.01 | |
| 0×14 | 10 | 10 | 18.00 | 33.73 | 1.12 | 3.13±0 | |||
| 250×14 | 10 | 10 | 19.00 | 32.18 | 0.94 | 1.37±0.45 | 56.23 | ＜0.01 | |
| 500×14 | 10 | 10 | 20.00 | 34.35 | 1.03 | 1.48±0.44 | 55.27 | ＜0.01 | |
| 0×21 | 10 | 8 | 19.00 | 33.13 | 0.67 | 4.15±0 | |||
| 250×21 | 10 | 10 | 18.00 | 27.35 | 0.45 | 3.21±0.65 | 22.65 | ＞0.05 | |
| 500×21 | 10 | 10 | 20.00 | 26.05 | 0.29 | 2.50±0.62 | 39.76 | ＜0.05 | |
Three, the administration at intermittence of inoculation back is to the influence of mouse entity tumor
For S-180 and U-14 entity tumor, behind conventional inoculated tumour, intermittently respectively be administered once in 1,3,7 day, the drug suspension of the present invention of each oral 250mg and 500mg/kg, each organizes 21 days mensuration tumor control rates after administration.Tumor weight average that administration is as a result respectively organized is more than or equal to matched group, and blanking time is long more, and growth of tumor speed is fast more, and the mortality rate of animal is also high more, and therefore the interval administration of inoculation back does not have inhibitory action to mouse entity type transplantation tumor.
Four, medicine of the present invention and ametycin share the influence to mouse entity type tumor
Give drug suspension of the present invention and the MMC of lumbar injection 1.0mg/kg/ day of oral 250mg of mice and 500mg/kg simultaneously, observation is to the influence of S-180 and U-14 solid type transplanted tumor, experiment shows, both share the curative effect that does not influence MMC, and the active anticancer of MMC is had in various degree raising.
The results are shown in following table 10
| The tumor strain | Medicine | Dosage ml/kg/ day mg | Route of administration | Number of animals | Body weight (g) | Tumor weight (g) | The P value | ||||
| Beginning | The end | Beginning | The end | The day increment | Average tumor weight ± standard error | Suppression ratio | |||||
| S-180 | The suspension normal saline | 0.5ml ×10 0.9mg | P.O i.P | 10 | 9 | 22.0 | 26.8 | 0.48 | 2.54±0 | ||
| Suspension MMC | 0.5ml ×10 1.0mg | P.O i.P | 10 | 10 | 19.0 | 21.3 | 0.23 | 1.76±0.29 | 30.71 | ＜0.05 | |
| The red MMC of prunus mume (sieb.) sieb.et zucc. | 250ml ×10 1.0mg | P.O i.P | 10 | 10 | 22.0 | 26.2 | 0.43 | 1.48±0.36 | 43.70 | ＜0.01 | |
| The red MMC of prunus mume (sieb.) sieb.et zucc. | 500ml ×10 1.0mg | P.O i.P | 10 | 10 | 22.0 | 25.3 | 0.33 | 0.97±0.31 | 61.81 | ＜0.001 | |
| u-14 | The suspension normal saline | 0.5ml ×10 0.9mg | P.O i.P | 10 | 10 | 21.0 | 25.4 | 0.44 | 1.68±0 | ||
| Suspension MMC | 0.5ml ×10 1.0mg | P.O i.P | 10 | 9 | 19.0 | 21.4 | 0.24 | 1.04±0.30 | 38.10 | ＜0.05 | |
| The red MMC of prunus mume (sieb.) sieb.et zucc. | 250ml ×10 1.0mg | P.O i.P | 10 | 10 | 19.0 | 21.4 | 0.24 | 0.95±0.35 | 43.45 | ≤0.05 | |
| The red MMC of prunus mume (sieb.) sieb.et zucc. | 500ml ×10 1.0mg | P.O i.P | 10 | 9 | 20.0 | 22.6 | 0.26 | 0.70±0.27 | 58.33 | ＜0.01 | |
Five, toxicity test
1, acute toxicity testing: with the Kunming mouse of 18～22 grams, male and female half and half are divided into five groups, and 10 every group, an oral administration was observed 72 hours, and trying to achieve median lethal dose(LD 50) by each group mortality rate by karber's method is 2.475 ± 0.26g/kg.
2, sub-acute toxicity test: select body weight 160 ± 10g for use, healthy rat, male and female half and half are divided four groups.Every group 5, distinguish oral drug suspension 200mg/kg of the present invention every day, 300mg/kg, 500mg/kg, matched group is given the equal-volume solvent, and successive administration 14 days found that, and the administration treated animal increases with matched group does not have notable difference.This drug toxicity is low, and safety coefficient is big.
The present invention obtains significant curative effect on clinical treatment, use through clinical 200 routine patients, and total effective rate reaches more than 90%, and its statistical result sees the following form 11
| All kinds of inflammatory patients | All kinds of tumor patients | All kinds of dermatosis patients | |
| Take a turn for the better | 80 | 35 | 10 |
| Cure | 35 | 20 | 10 |
| Invalid | 5 | 5 | 0 |
| Amount to | 120 | 60 | 20 |
| Effective percentage | 95％ | 97％ | 100％ |
Model case:
1, poplar XX, the man, 35 years old, the right axillary lymph inflammation of binding up one's hair was taken this medicine and is taken effect after five days, the back recovery from illness of two weeks.
2, Lee XX, the man, 50 years old, suffer from a mouthful cellulitis, there is not positive effect with the streptomycin long-term treatment, use the back healing of one week of this medicine.
3, Guo XX, the woman, 55 years old, suffer from mastitis, through antibiotic therapy, effect is undesirable, can not perform the operation but have, and taking this medicine after one month, is almost recovered.
4, Liu XX, the man, 30 years old, grow the granulous white bubble of rice on the arm, pain unbearably, interior take and outside after one week of application, transference cure.
5, open XX, the man, 46 years old, to suffer from and trike the nevus skin ulcer, the many places therapeutic effect is poor, and outbreak repeatedly, has a strong impact on work and life, is using this medicine to be clearly better after two months continuously.
6, bavin XX, the woman, 32 years old, shoulder grew bubble, was fibroma after diagnosing, recurrence again after underwent operative is taken out, bubble disappears after taking this medicine.
7, king XX, the woman, 56 years old, suffer from hysteromyoma 1 * 1.5cm, to take this medicine and check after January, hysteromyoma disappears, more not recurrence.
The specific embodiment
Embodiment 1: a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin, and it is formulated by weight by following medicine:
Accurately take by weighing Stigma Croci 12 grams, Flos Carthami 136 grams, Realgar 200 grams, Venenum Bufonis (system) 64 grams, Olibanum (system) 120 grams, Myrrha (processed) 120 grams, Sanguis Draxonis 40 grams, Lignum Aquilariae Resinatum 80 grams, Borax 80 grams, Herba Taraxaci 240 grams, Radix Et Rhizoma Rhei 120 grams, Semen Lepidii (Semen Descurainiae) 40 grams, Squama Manis 160 grams, Calculus Bovis 4 grams, Moschus 4 grams, Margarita 2 grams, Fel Ursi 2 grams, Scolopendra 7.5 grams, Flos Lonicerae 160 grams, Cinnabaris 320 grams, Borneolum Syntheticum 40 grams
Cinnabaris, Realgar, crushing pearl are impalpable powder, to remove Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis all the other 13 flavor pulverizing medicinal materials in addition again and become fine powder, with above-mentioned all fine powders mix back (reserve 1/5th Cinnabaris fine powders keep supplying clothing with) again with Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis facing-up, sieve, mix homogeneously, use the Co-60 radiation sterilization, microbiological indicator after the assay was approved; Make the watered pill.
Embodiment 2: a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin, and it is formulated by weight by following medicine:
Accurately take by weighing Stigma Croci 10 grams, Flos Carthami 126 grams, Realgar 190 grams, Venenum Bufonis (system) 60 grams, Olibanum (system) 110 grams, Myrrha (processed) 110 grams, Sanguis Draxonis 35 grams, Lignum Aquilariae Resinatum 70 grams, Borax 70 grams, Herba Taraxaci 230 grams, Radix Et Rhizoma Rhei 110 grams, Semen Lepidii (Semen Descurainiae) 35 grams, Squama Manis 150 grams, Calculus Bovis 3 grams, Moschus 3 grams, Margarita 1 gram, Fel Ursi 1 gram, Scolopendra 6.5 grams, Flos Lonicerae 150 grams, Cinnabaris 310 grams, Borneolum Syntheticum 35 grams
Cinnabaris, Realgar, crushing pearl are impalpable powder, to remove Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis all the other 13 flavor pulverizing medicinal materials in addition again and become fine powder, with above-mentioned all fine powders mix back (reserve 1/5th Cinnabaris fine powders keep supplying clothing with) again with Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis facing-up, sieve, mix homogeneously, use the Co-60 radiation sterilization, microbiological indicator after the assay was approved; Make the watered pill.
Embodiment 3: a kind of tongue dropping medicine pill of eliminating inflammation and expelling toxin, and it is formulated by weight by following medicine:
Accurately take by weighing Stigma Croci 14 grams, Flos Carthami 146 grams, Realgar 210 grams, Venenum Bufonis (system) 70 grams, Olibanum (system) 130 grams, Myrrha (processed) 130 grams, Sanguis Draxonis 45 grams, Lignum Aquilariae Resinatum 90 grams, Borax 90 grams, Herba Taraxaci 250 grams, Radix Et Rhizoma Rhei 130 grams, Semen Lepidii (Semen Descurainiae) 45 grams, Squama Manis 170 grams, Calculus Bovis 5 grams, Moschus 5 grams, Margarita 3 grams, Fel Ursi 3 grams, Scolopendra 8.5 grams, Flos Lonicerae 170 grams, Cinnabaris 330 grams, Borneolum Syntheticum 45 grams
Cinnabaris, Realgar, crushing pearl are impalpable powder, to remove Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis all the other 13 flavor pulverizing medicinal materials in addition again and become fine powder, with above-mentioned all fine powders mix back (reserve 1/5th Cinnabaris fine powders keep supplying clothing with) again with Calculus Bovis, Borneolum Syntheticum, Moschus, Fel Ursi, Venenum Bufonis facing-up, sieve, mix homogeneously, use the Co-60 radiation sterilization, microbiological indicator after the assay was approved; Make the watered pill.
Claims (2)
1, a kind of pill of eliminating inflammation and expelling toxin is characterized in that it is formulated by weight by following medicine:
190～210 parts of 126～146 portions of Realgars of 10～14 parts of Flos Carthamis of Stigma Croci
110～130 parts of 110～130 parts of Myrrhas of 60～70 parts of Olibanums of Venenum Bufonis
70～90 parts of 70～90 parts of Boraxs of 35～45 portions of Lignum Aquilariae Resinatum of Sanguis Draxonis
35～45 parts of 110～130 parts of Semen Lepidii (Semen Descurainiae)s of 230～250 parts of Radix Et Rhizoma Rhei of Herba Taraxaci
3～5 parts in 3～5 parts of Moschus of 150～170 parts of Calculus Boviss of Squama Manis
6.5～8.5 parts of 1～3 part of Scolopendras of 1～3 part of Fel Ursi of Margarita
35～45 parts of 310～330 parts of Borneolum Syntheticums of 150～170 parts of Cinnabaris of Flos Lonicerae.
2, the pill of eliminating inflammation and expelling toxin according to claim 1 is characterized in that it is formulated by weight by following medicine:
64 parts of 200 parts of Venenum Bufoniss of 136 portions of Realgars of 12 parts of Flos Carthamis of Stigma Croci
80 parts of 40 portions of Lignum Aquilariae Resinatum of 120 parts of Sanguis Draxonis of 120 parts of Myrrhas of Olibanum
40 parts of 120 parts of Semen Lepidii (Semen Descurainiae)s of 240 parts of Radix Et Rhizoma Rhei of 80 parts of Herba Taraxacis of Borax
2 parts of 4 parts of Margaritas of 4 parts of Moschus of 160 parts of Calculus Boviss of Squama Manis
320 parts in 160 parts of Cinnabaris of 7.5 portions of Flos Loniceraes of 2 parts of Scolopendras of Fel Ursi
40 parts of Borneolum Syntheticums.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100128078A CN1310659C (en) | 2005-09-09 | 2005-09-09 | Tongue dropping medicine pill for diminishing inflammation and detoxicating |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100128078A CN1310659C (en) | 2005-09-09 | 2005-09-09 | Tongue dropping medicine pill for diminishing inflammation and detoxicating |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739706A CN1739706A (en) | 2006-03-01 |
| CN1310659C true CN1310659C (en) | 2007-04-18 |
Family
ID=36092331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100128078A Active CN1310659C (en) | 2005-09-09 | 2005-09-09 | Tongue dropping medicine pill for diminishing inflammation and detoxicating |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1310659C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041015B (en) * | 2007-04-19 | 2011-05-18 | 韩曙光 | Medicine for treating hyperplasia of mammary glands |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417795B (en) * | 2013-08-12 | 2015-03-18 | 江西天施康中药股份有限公司 | Medicine composition for detoxicating and relieving sore throat, and preparation method of medicine composition |
| CN103721011B (en) * | 2013-12-14 | 2015-12-09 | 郑明立 | A kind of medicine for the treatment of furuncle and preparation method thereof |
| CN104173409A (en) * | 2014-08-06 | 2014-12-03 | 四川金堂海纳生物医药技术研究所 | Traditional Chinese medicine detoxification pill for treating pituitary adenoma and preparation method thereof |
| CN105213967A (en) * | 2015-09-30 | 2016-01-06 | 郑文修 | A kind of Chinese medicine preparation for the treatment of malignant tumor |
| CN105395752A (en) * | 2015-11-30 | 2016-03-16 | 郭上蔚 | Medicine for treating furuncle and malignant sore pyogenic infections and preparing method thereof |
| CN105748728A (en) * | 2016-04-29 | 2016-07-13 | 孙玉鸣 | Traditional Chinese medicine composition for treating skin diseases and hyperplasia of mammary glands and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279958A (en) * | 2000-04-10 | 2001-01-17 | 张继友 | Medicine for curing osteomyelitis and its preparing method |
| CN1315191A (en) * | 2000-03-30 | 2001-10-03 | 陈江辉 | Oral liquid for clearing heat and detoxicating and its preparing process |
-
2005
- 2005-09-09 CN CNB2005100128078A patent/CN1310659C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315191A (en) * | 2000-03-30 | 2001-10-03 | 陈江辉 | Oral liquid for clearing heat and detoxicating and its preparing process |
| CN1279958A (en) * | 2000-04-10 | 2001-01-17 | 张继友 | Medicine for curing osteomyelitis and its preparing method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101041015B (en) * | 2007-04-19 | 2011-05-18 | 韩曙光 | Medicine for treating hyperplasia of mammary glands |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739706A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1310659C (en) | Tongue dropping medicine pill for diminishing inflammation and detoxicating | |
| CN1302793C (en) | Cure-all ointment for treating burns and scald | |
| CN1679745A (en) | External-applied medicine for treating burn, valnus and local tumor inflammation | |
| CN101041043A (en) | Liver cancer treating traditional Chinese medicine | |
| CN1836715A (en) | External use medicine for quickly treating herpes zoster | |
| CN1270746C (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN1189197C (en) | Traditional Chinese medicine having effects of reducing inflammation, stopping blooding, stopping pain, promoting blood circulation and promoting tissue regeneration | |
| CN1279952C (en) | Medicine for treating burns and scalds | |
| CN1259087C (en) | Medicine for treating trauma and sores and its preparing process | |
| CN109010495B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1180833C (en) | Chinese medicine against skin and external diseases | |
| CN1444967A (en) | Chinese herbal medicine preparation for treating burns | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1296034C (en) | Halitosis removing toothpaste | |
| CN1836702A (en) | Medicine for treating tumour and its preparing method | |
| CN1233313C (en) | Gel agent for treating acne and its preparation method | |
| CN1192365A (en) | Traditional Chinese medicine for treating mastosis | |
| CN1745845A (en) | Chinese medicinal composition for treating and inhibiting tumor, its preparation and use | |
| CN1850224A (en) | Medicine for treating scald and burn and preparing method | |
| CN1111419C (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular vessel apoplexy and premonitory apoplexy symptom and preparation method thereof | |
| CN1121237C (en) | Health-care products for regulating immunological function and delaying senility | |
| CN1954835A (en) | Sea-buckthorn plant preparation and its preparation method | |
| CN1839882A (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN1836683A (en) | Medicine for treating tumour and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG FENG Free format text: FORMER OWNER: HAO TIANFA Effective date: 20101008 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Feng Inventor before: Hao Tianfa |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HAO TIANFA TO: WANG FENG Free format text: CORRECT: ADDRESS; FROM: 043100 NO.30, FUJUN LANE, XINJIANG COUNTY, SHANXI PROVINCE TO: 100176 NO.1, DIZE NORTH STREET, BEIJING ECONOMIC AND TECHNOLOGY DEVELOPMENT ZONE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101008 Address after: 100176 No. 1 North Ze street, Beijing economic and Technological Development Zone Patentee after: Wang Feng Address before: 043100 Shanxi province Xinjiang county Jun Xiang No. 30 Patentee before: Hao Tianfa |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20180413 Address after: 043100 Shanxi city in Yuncheng Province, Xinjiang County House Road No. 70 Patentee after: Lang Zhi group double Pharmaceutical Co., Ltd. Address before: 100176 No. 1 North Ze street, Beijing economic and Technological Development Zone Patentee before: Wang Feng |
|
| TR01 | Transfer of patent right |